Richiedi una copia del documento: Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response

Captcha code
Annulla